Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IBI310 + SHR-1316 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IBI310 | IBI-310|IBI 310 | CTLA4 Antibody 33 | IBI310 is an antibody targeting CTLA4 (CD152), which potentially induces antitumor activity (PMID: 38881798). | |
| SHR-1316 | SHR 1316|SHR1316|Adebrelimab|HTI 1088|HTI-1088|HTI1088 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | SHR-1316 is a monoclonal antibody that targets PD-L1 (CD274), potentially resulting in antitumor activity (PMID: 33760397). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|